Tags

Type your tag names separated by a space and hit enter

Messenger RNA vaccines against SARS-CoV-2.
Cell. 2021 03 18; 184(6):1401.Cell

Abstract

The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3-4 weeks apart. To view this Bench to Bedside, open or download the PDF.

Authors+Show Affiliations

Scripps Research, La Jolla, CA, USA. Electronic address: etopol@scripps.edu.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33740443

Citation

Topol, Eric J.. "Messenger RNA Vaccines Against SARS-CoV-2." Cell, vol. 184, no. 6, 2021, p. 1401.
Topol EJ. Messenger RNA vaccines against SARS-CoV-2. Cell. 2021;184(6):1401.
Topol, E. J. (2021). Messenger RNA vaccines against SARS-CoV-2. Cell, 184(6), 1401. https://doi.org/10.1016/j.cell.2020.12.039
Topol EJ. Messenger RNA Vaccines Against SARS-CoV-2. Cell. 2021 03 18;184(6):1401. PubMed PMID: 33740443.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Messenger RNA vaccines against SARS-CoV-2. A1 - Topol,Eric J, Y1 - 2021/01/13/ PY - 2021/3/19/entrez PY - 2021/3/20/pubmed PY - 2021/4/1/medline SP - 1401 EP - 1401 JF - Cell JO - Cell VL - 184 IS - 6 N2 - The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3-4 weeks apart. To view this Bench to Bedside, open or download the PDF. SN - 1097-4172 UR - https://www.unboundmedicine.com/medline/citation/33740443/Messenger_RNA_vaccines_against_SARS_CoV_2_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0092-8674(20)31761-X DB - PRIME DP - Unbound Medicine ER -